Invokana Studies on Weight Management in Diabetic Patients
In several clinical studies, weight loss was assessed as a secondary endpoint during the 26-week or 52-week periods.
The pattern of weight loss with Invokana was generally consistent across studies, with a reduction seen by week 12, and with continued weight loss over the 26-week or 52-week periods.
Across these 3 studies, a greater body weight reduction was seen with Invokana 300 mg compared to Invokana 100 mg.
Change in Weight (kg) From Baseline in Invokana Studies
Invokana Studies on Weight Management in Non-Diabetic Patients
An unpublished clinical study evaluated the safety and effectiveness of Invokana 50 mg, 100 mg, and 300 mg given once daily for 12 weeks on weight reduction in overweight or obese non-diabetic patients. However, the results of this study have not been published.
Farxiga Studies on Weight Management in Diabetic Patients
A phase 3 study evaluated the change in total body weight (TBW) as a primary endpoint. Patients treated with Farxiga 10 mg added to metformin showed greater 24 and 102-week reductions in TBW compared to patients treated with placebo added to metformin (-2.96 kg compared to -0.88 kg at week 24 and -4.54 kg versus-2.12 kg at week 102).
Weight loss was assessed as a secondary endpoint in 7 placebo-controlled studies and the results are shown in the table below.
Change in Weight (kg) From Farxiga Studies
Farxiga Studies on Weight Management in Non-Diabetic Patients
Currently, there are no clinical studies evaluating Farxiga’s effect on body weight in non-diabetic patients.
Next: Side Effects, Cost, Risk Versus Benefit